BNTX
HealthcareBioNTech SE · Biotechnology · $23B
What is BioNTech SE?
BioNTech SE is a German biotechnology company focused on developing mRNA-based immunotherapies for cancer and infectious diseases, headquartered in Mainz, Germany.
BioNTech develops a broad pipeline of cancer immunotherapies, including mRNA-based treatments, neoantigen therapies, CAR-T cell therapies, and monoclonal antibodies. The company targets a wide range of tumor types — from melanoma and lung cancer to pancreatic cancer — with multiple candidates across Phase I and Phase II clinical trials.
BioNTech was founded in 2019 and is headquartered in Mainz, Germany.
- mRNA cancer vaccine candidates (FixVac platform)
- Personalized neoantigen immunotherapies
- CAR-T cell therapies for solid tumors
- Checkpoint immunomodulators and RiboCytokines
Is BNTX a Good Stock to Buy?
UQS Score rates BNTX as Poor overall.
Among the five pillars, Risk comes in at a Neutral rating — a relative bright spot suggesting the balance sheet carries some stability. Valuation is rated Elevated, meaning the market is pricing in expectations that the current fundamentals do not yet support.
Quality, Moat, and Growth are all rated Weak, reflecting the challenges of a pipeline-stage biotech with limited commercial revenue and no established competitive advantages.
See the full pillar breakdown and financial metrics by signing up for a Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BNTX pay dividends?
No — BioNTech SE does not currently pay a dividend.
BioNTech does not currently pay a dividend. Like most clinical-stage biotechs, the company reinvests available capital into research, clinical trials, and pipeline expansion rather than returning cash to shareholders.
When does BNTX report earnings?
BioNTech reports earnings on a quarterly cadence, typical for US-listed equities.
As a biotech with a pipeline-heavy model, quarterly results are often shaped by milestone events, partnership revenues, and R&D spending rather than consistent product sales. Investors should watch for clinical trial updates alongside financial results.
For the most recent quarter's results, see BioNTech's investor relations page.
BNTX Price History
-44.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in BioNTech SE?
Based on BioNTech SE's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does BioNTech do?
BioNTech develops immunotherapies targeting cancer and infectious diseases. Its pipeline spans mRNA cancer vaccines, personalized neoantigen treatments, CAR-T cell therapies, and monoclonal antibodies, with candidates in multiple Phase I and Phase II clinical trials across a range of tumor types.
Does BNTX pay dividends?
No, BioNTech does not pay a dividend. The company directs its capital toward clinical development and pipeline expansion, which is common for biotechs at this stage of growth.
When does BNTX report earnings?
BioNTech follows a standard quarterly reporting schedule. For exact dates and the most recent results, visit BioNTech's official investor relations page.
Is BNTX a good stock to buy?
UQS Score rates BNTX as Poor, with Weak ratings across Quality, Moat, and Growth pillars. Risk is Neutral, and Valuation is Elevated. Investors should review the full pillar breakdown before drawing conclusions — available to Pro members.
Is BNTX overvalued?
The UQS Valuation pillar for BNTX is rated Elevated, suggesting the current market price reflects expectations that go beyond what the company's fundamentals currently support. This is a common dynamic for pipeline-stage biotechs.
What is BNTX's market cap bracket?
BioNTech is classified as a large-cap company, placing it among the larger publicly traded biotechnology firms despite its pipeline-stage business model.
Is BNTX a long-term quality investment?
From a quality standpoint, UQS rates BNTX as Poor, with weakness across Quality, Moat, and Growth pillars. Long-term potential depends heavily on clinical trial outcomes and commercial execution — factors the UQS framework monitors over time.
What sector does BNTX belong to?
BioNTech operates in the Healthcare sector, specifically within biotechnology. The company focuses on oncology and infectious disease immunotherapy, competing in one of the most research-intensive areas of the sector.
Unlock Full BNTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar score breakdown for BNTX
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare BNTX against sector peers on a standardized quality framework
- ✓Track score changes as new earnings and pipeline data emerge
Pro Analysis
BNTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 14.7 | 11.3 | 19.0 | 0.6 | 47.1 | 0.0 | -0.1 |
| May 16, 2026 | 14.8 | 11.3 | 19.0 | 0.7 | 47.1 | 0.0 | 0.0 |
| May 14, 2026 | 14.8 | 11.3 | 19.0 | 0.9 | 47.1 | 0.0 | -0.1 |
| May 11, 2026 | 14.9 | 11.3 | 19.0 | 1.2 | 47.1 | 0.0 | +2.9 |
| May 10, 2026 | 12.0 | 0.0 | 19.0 | 1.2 | 47.1 | 0.0 | +0.2 |
| May 9, 2026 | 11.8 | 0.0 | 19.0 | 0.0 | 47.1 | 0.0 | -1.3 |
| May 8, 2026 | 13.1 | 4.2 | 19.0 | 1.1 | 47.1 | 0.0 | -0.1 |
| May 5, 2026 | 13.2 | 4.2 | 19.0 | 1.5 | 47.1 | 0.0 | 0.0 |
| May 4, 2026 | 13.2 | 4.2 | 19.0 | 1.6 | 47.1 | 0.0 | 0.0 |
| May 2, 2026 | 13.2 | 4.2 | 19.0 | 1.5 | 47.1 | 0.0 | 0.0 |
BNTX — Pillar Breakdown
Quality
— 11.3/100 (25%)BioNTech SE currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 0.6/100 (20%)BioNTech SE faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)BioNTech SE has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)BioNTech SE appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 19/100 (25%)BioNTech SE operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BNTX.
Score Composition
Financial Data
More Stock Analysis
How is the BNTX UQS Score Calculated?
The UQS (Unified Quality Score) for BioNTech SE is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BioNTech SE's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BioNTech SE is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.